COSM— Cosmos Health Inc.

Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed

Cosmos Holdings Non-GAAP EPS of -$0.12, revenue of $65.27M

3 things to look out for on Monday

Cosmos Health sees strong growth, unaffected by Middle East tensions

Cosmos Health regains compliance with Nasdaq’s listing rule